Product Overview
[Drug Name]
Generic Name: Amlodipine Maleate Dispersible Tablets
Trade Name: Amlodipine Maleate Dispersible Tablets 5mg x 20 tablets
Pinyin Code: ZuoPing MaLaiSuanAnLvDiPingFenSanPian 5mg x 2OPian
[Main Ingredient]
Amlodipine Maleate.
[Indications/Main Functions]
1. Hypertension: This product can be used alone or in combination with other antihypertensive drugs. 2. Chronic stable angina and variant angina: This product can be used alone or in combination with other antianginal drugs.
[Specifications]
5mg x 20 tablets
[Dosage and Administration]
The usual starting oral dose is 5mg once daily, with a maximum of 10mg once daily. For thin individuals, those with frail constitutions, the elderly, or those with impaired liver function, starting with 2.5mg once daily is recommended. Patients taking other antihypertensive drugs should also start with this dose. The dosage should be adjusted according to individual needs. The adjustment period should be no less than 7-14 days so that the doctor can fully evaluate the patient's response to the dose. However, the adjustment speed can be accelerated under the premise of clinical guarantee. The recommended dose for the treatment of angina pectoris is 5-10 mg. Elderly patients or those with impaired liver function need to reduce the dose.
[Adverse Reactions]
See the instructions for details
[Contraindications]
Patients who are allergic to dihydropyridine drugs or any ingredients in this product are contraindicated.
[Precautions]
(1) Angina pectoris and/or myocardial death: rare. Patients with severe obstructive coronary artery disease may experience an increase in the frequency, duration and/or severity of angina attacks or develop acute myocardial infarction when starting treatment with calcium channel antagonists or increasing the dose. The mechanism is unknown. (2) Hypotension: Since this product gradually produces a vasodilator effect, acute hypotension is generally rare after oral administration. However, caution should still be exercised when this product is used in combination with other peripheral vasodilators, especially for patients with severe aortic valve stenosis. (3) Patients with heart failure: Calcium channel blockers should be used with caution in patients with heart failure. (4) Patients with hepatic insufficiency: This product should be used with caution in patients with severe hepatic insufficiency. (5) Patients with renal failure: The starting dose for patients with renal failure can remain unchanged. (6) Discontinuation of beta-blockers: This product has no protective effect against rebound symptoms caused by sudden discontinuation of beta-blockers. Therefore, the dose should still be gradually reduced when discontinuing beta-blockers. (7) This product can be used safely in patients with obstructive pulmonary disease, well-compensated heart failure, peripheral vascular disease, diabetes, and lipid disorders.
